Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Inhibitors: The Effect of Concurrent Medications on Patient Outcomes
Oncology · 2025
DOI: 10.1159/000543163 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2025. Verfasst von Jussi Koivunen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center and Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Introduction
EGFR-tyrosine kinase inhibitor (TKI)-induced rash can be alleviated with tetracyclines (TCN) and topical corticosteroids (TCS), whereas drugs for acid-related disorders (DARDs) can affect EGFR-TKI absorption. The present study investigated the concomitant use of TCNs, TCSs, and DARDs with EGFR-TKIs in non-small cell lung cancer (NSCLC) and whether these affect patient outcomes.
Methods
We retrospectively collected data from all patients (n = 1,498) who had purchased for EGFR-TKIs (erlotinib, gefitinib, and afatinib) in Finland between 2011 and 2020. Overall survival (OS) and time-on-treatment (ToT) were analyzed from the first EGFR-TKI purchase.
Results
Early TCN purchases were registered in 298 (19.6%) patients; early TCS and DARD purchases were observed in 154 (10.1%) and 192 (12.9%), while similar percentages were detected in the EGFR mutant cohort. In the entire cohort, early purchase of TCSs and TCNs was associated with improved ToT, OS, and DARDs with inferior outcomes. In the multivariate analysis, TCSs retained their significance in ToT (HR: 0.78; 95% CI: 0.66–0.94), TCNs in OS (HR: 0.73; 95% CI: 0.63–0.84), and DARDs in both (HR: 1.28; 95% CI: 1.091–1.495; HR: 1.19; 95% CI: 1.01–1.41). In the EGFR mutant cohort, similar nonsignificant trends were observed for TCNs, TCSs and DARDs. In the analysis according to EGFR-TKI, erlotinib users had improved outcomes when early TCN or TCS purchases were registered, whereas DARDs were associated with worse outcomes among gefitinib users.
Conclusions
Among EGFR-TKI-treated NSCLCs, the use of TCN, TCS, and DARD can affect treatment outcomes that should be considered in optimal patient care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Center and Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
- Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland.
Zitieren
APA
Koivunen, J., Manninen, O., Iivanainen, S., Arffman, M., & Koivunen, J. P. (2025). Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Inhibitors: The Effect of Concurrent Medications on Patient Outcomes. Oncology. https://doi.org/10.1159/000543163
Vancouver
Koivunen J, Manninen O, Iivanainen S, Arffman M, Koivunen JP. Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Inhibitors: The Effect of Concurrent Medications on Patient Outcomes. Oncology. 2025. doi:10.1159/000543163
BibTeX
@article{Koivunen2025,
author = {Koivunen, Jussi and Manninen, Otto and Iivanainen, Sanna and Arffman, Martti and Koivunen, Jussi Pekka},
title = {Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Inhibitors: The Effect of Concurrent Medications on Patient Outcomes},
journal = {Oncology},
year = {2025},
doi = {10.1159/000543163}
}
EUVIMED